PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma

PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Introduction Intratumoral administration of pexa-vec (Pexastimogene Devacirepvec), an oncolytic and immunotherapeutic vaccinia virus. given to patients with hepatocellular carcinoma (HCC), is associated with both local and distant tumor responses. We hypothesized subsequent treatment with sorafenib...

Full description

Bibliographic Details
Main Authors: Ghassan K. Abou-Alfa, Peter R. Galle, Yee Chao, Joseph Erinjeri, Jeong Heo, Mitesh J. Borad, Angelo Luca, James Burke, Adina Pelusio, Delphine Agathon, Monika Lusky, Caroline Breitbach, Shukui Qin, Edward Gane
Format: Article
Language:English
Published: Karger Publishers 2023-09-01
Series:Liver Cancer
Online Access:https://beta.karger.com/Article/FullText/533650

Similar Items

Similar Items